Peptide & Experimental
Matrixyl (palmitoyl pentapeptide)
Cosmetic collagen signal peptide (topical) · Matrixyl 3000, Palmitoyl Pentapeptide-4, Palmitoyl Tripeptide-1
Matrixyl is the anti-aging classic in serums: a short peptide with a fatty acid tail that is supposed to signal a need for repair to the skin and thus stimulate collagen production. It is the cosmetic peptide with the most solid clinical study. That study, however, belongs to the older variant, not to the one found in most products today.
In short
Matrixyl is palmitoyl pentapeptide-4, the amino acid sequence KTTKS with palmitic acid attached. In a double-blind, placebo-controlled split-face study with 93 women over 12 weeks, a cream with this peptide improved wrinkles and fine lines measurably more than the same cream without the peptide. In a small head-to-head comparison it performed better than the muscle peptide Argireline. Tolerability is good; the effect is moderate and slow. For Matrixyl 3000, the combination of two other peptides, we found no randomized study of its own in humans. And whether the peptides reach the collagen-producing cells in the dermis is open.
What it is
Several molecules hide behind the name Matrixyl. The original is palmitoyl pentapeptide-4: the five amino acids lysine, threonine, threonine, lysine, serine, KTTKS for short, with palmitic acid attached. The molecular weight is 802.1 grams per mole. The fatty acid makes the inherently water-loving peptide more fat-friendly, so that it can be incorporated into a cream at all and reach the uppermost layer of the skin.
Matrixyl 3000 is something else: the combination of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7. This is the variant listed in most serums today. The difference matters for the assessment, because the clinical evidence rests on the older pentapeptide.
How it is supposed to work
The idea is called a signal peptide. KTTKS is a fragment of the kind produced when collagen is broken down. When such a fragment occurs in the skin, the skin reads this as a need for repair and builds new collagen. The peptide thus simulates this state without any collagen having been broken down.
In cell culture, this chain is well reproduced. According to reviews, the peptide binds to a cell surface receptor in the dermis and, via signaling pathways, increases the production of type I and III collagen, slows collagen breakdown and stimulates hyaluronic acid production in fibroblasts. In a series of cell experiments, the peptide packaged in liposomes stimulated collagen production in human fibroblasts more strongly than the free peptide and more strongly than ascorbic acid as a positive control.
In humans, the measurements stop earlier. A 2026 study stripped the stratum corneum layer by layer in 3 volunteers after application of a Matrixyl 3000 serum and analyzed it by mass spectrometry. Both peptides were detectable in every layer of the stratum corneum, and the signal strength decreased inward. The second finding is notable: the signal dropped immediately, which suggests that the peptides sit on the cell surfaces and do not enter the cells. Whether they reach the living fibroblasts in the dermis has therefore not been shown.
How strong the effect is
The peptide is not retinol and not botulinum toxin. The studies are about measurably reduced wrinkle depth over weeks, not a visible leap. The meta-analysis on peptides against skin aging puts this in context: across 19 randomized trials with 1,341 participants, the pooled effect on wrinkles was small, and it was mainly due to orally taken polypeptides. Moisture and radiance improved more clearly, elasticity and skin density inconsistently.
What distinguishes Matrixyl from most cosmetic peptides is not the size of the effect but the quality of the evidence: a genuine split-face study with an identical base and 93 participants. Few have that.
What is well supported
The key study is a double-blind, placebo-controlled, split-face, left-right randomized study with 93 white women aged 35 to 55 over 12 weeks. A moisturizer was compared with the same cream containing 3 ppm palmitoyl-KTTKS. The improvement in wrinkles and fine lines was significant compared with the control, in two independent assessments: in quantitative technical image analysis and in assessment by trained graders. The participants reported the same in their self-assessment. The peptide was well tolerated by the skin.
In addition, there is a head-to-head comparison with the better-known muscle peptide. In a double-blind, randomized study with 21 Indonesian women over 8 weeks, cream with palmitoyl pentapeptide-4, cream with acetyl hexapeptide-3 and placebo were applied to the eye area and assessed with several skin measuring devices, photography and a crow’s feet scale. Palmitoyl pentapeptide-4 performed better than both other groups. The study is small; the authors themselves call it a pilot study.
Tolerability is also well supported. In the 12-week clinical study there were no abnormalities, and in a bioinformatic safety assessment palmitoyl pentapeptide-4 showed sequence similarity to skin proteins such as collagen, elastin and fibronectin, without the red flags that the same tools correctly identified in known toxins.
What the studies show
Robinson et al., Int J Cosmet Sci 2005
Double-blind, placebo-controlled, split-face, left-right randomized, 93 women aged 35 to 55, 12 weeks. Moisturizer versus the same cream with 3 ppm palmitoyl-KTTKS. Wrinkles and fine lines were assessed by technical image analysis and trained graders, both in favor of the peptide. Limitations: one population group, 12 weeks, wrinkles as the endpoint, manufacturer setting.
Aruan et al., J Clin Aesthet Dermatol 2023
Double-blind and randomized, 21 Indonesian women aged 26 to 55, 8 weeks, three groups: palmitoyl pentapeptide-4, acetyl hexapeptide-3 and placebo, applied twice daily to the eye area. Palmitoyl pentapeptide-4 came out ahead according to measurement data, photos and self-assessment. With around 7 participants per group, a pilot study.
Trzaska et al., Int J Pharm 2026
Not proof of efficacy, but the most important mechanistic finding in humans. In 3 volunteers, the stratum corneum was stripped layer by layer after application of a Matrixyl 3000 serum and analyzed by mass spectrometry, at exposure times of half an hour, 2 and 5 hours. Both peptides were detectable in all layers, with decreasing strength inward, and apparently lay on the cell surfaces rather than inside the cells.
Vitali et al., Pharmaceutics 2024
Cell culture in fibroblasts. Palmitoyl-KTTKS was incorporated into liposomes made from egg phosphatidylcholine, with particle sizes below 100 and below 200 nanometers. Packaged in liposomes, the peptide stimulated collagen production more strongly than the free peptide and more strongly than 1 mM ascorbic acid as a positive control. This supports the principle but says nothing about living skin under a cream.
Where the data stop
The biggest gap lies between what has been studied and what is on the shelf. The clinical evidence belongs to palmitoyl pentapeptide-4. For Matrixyl 3000, the combination of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7, we found no randomized study in humans that tests this combination alone against an identical base. Anyone who buys Matrixyl 3000 is not buying the product the good study rests on.
The chain of action has not been closed in humans either. It is established that the peptides reach all layers of the stratum corneum, apparently on the cell surfaces rather than inside the cells. Whether they reach the collagen-producing cells in the dermis and act there has not been measured. Receptor binding and increased collagen come from cell culture.
The clinical base is also narrow: two studies with 93 and 21 participants over 12 and 8 weeks, wrinkles as the endpoint, no tissue examination. This is exactly what the meta-analysis on peptides calls for: larger studies with standardized endpoints and skin biopsies. And one must not infer from one peptide to the next. With derivatives of KTTKS in cell culture, one variant increased collagen production, another reduced it at higher concentrations, and above certain concentrations cell tolerability declined. There is no study in humans on injected use.
Status, approval and legal
Palmitoyl pentapeptide-4 and the Matrixyl 3000 peptides are cosmetic ingredients and freely available in Germany in serums and creams. The European ingredient database was not accessible on September 30, 2026, so we do not state a European maximum concentration here. Cosmetics may not promise a medicinal effect; claims about new collagen formation in the dermis are close to this boundary. Injectable preparations are not approved medicines and may not be marketed in Germany; we do not give dosage information for them. The peptides are not named specifically in the 2026 Prohibited List. For an injected, unapproved preparation, the catch-all class S0 for non-approved substances applies according to its wording.
Safety
Applied to the skin, Matrixyl is well tolerated. In the 12-week clinical study with 93 participants, skin tolerability was unremarkable, and a review describes the substance as safe, non-irritating and non-sensitizing up to a concentration of 3 percent. In a bioinformatic safety assessment, palmitoyl pentapeptide-4 showed sequence similarity to collagen, elastin and fibronectin, without indications of toxicity or allergenic potential; the same tools correctly identified known toxins. This is, however, a prediction from databases, not a test in humans. A finding from cell culture calls for restraint at high concentrations: with derivatives of the peptide, cell tolerability dropped markedly above certain concentrations. So more is not automatically better here. There are no upper limits from EFSA or the BfR, because the substance is not a food. It has not been studied in pregnancy and breastfeeding. On irritated or injured skin and around the eyes, the same caution applies as with any cosmetic, and injections are not covered by any study in humans.
BK-Score Supported, with caveats
| Human evidence | 6 | |
|---|---|---|
| Mechanism | 5 | |
| Safety data | 5 | |
| Hype gap | 4 | |
| Track record of use | 8 |
The best-supported of the cosmetic peptides – topically and for the older variant: Robinson et al. (Int J Cosmet Sci 2005) tested, double-blind, placebo-controlled and split-face in 93 women over 12 weeks, a cream with 3 ppm palmitoyl-KTTKS against the same cream without the peptide and found significantly fewer wrinkles and fine lines in technical image analysis and grader assessment. In a small double-blind comparison study (Aruan 2023, 21 women, 8 weeks), palmitoyl pentapeptide-4 performed better than acetyl hexapeptide-3 and placebo. Collagen stimulation via the signal peptide principle has been reproduced in cell culture but not measured in humans: a mass spectrometry study in 3 volunteers shows the peptides in all layers of the stratum corneum, apparently on the cell surfaces rather than inside the cells (Trzaska 2026). Two gaps remain: for Matrixyl 3000 (palmitoyl tripeptide-1 plus tetrapeptide-7), today’s best-selling variant, no randomized study of its own in humans was found, and there is no human study on injectable use. That is exactly where the problem lies: solid topical evidence on one molecule is transferred to other molecules and to an untested form of use.
The score rates the state of knowledge, not the substance. “Safety data 9” means well studied – not harmless.
Subjective assessment by Biohacking Kompakt based on published scoring rules – not a scientific rating and not a medical recommendation. Rules and all ratings (German)
Frequently asked questions about Matrixyl (palmitoyl pentapeptide)
Does Matrixyl really work?
For palmitoyl pentapeptide-4 there is a double-blind split-face study with 93 women over 12 weeks in which wrinkles and fine lines decreased measurably more than with the same cream without the peptide. The effect is moderate and takes weeks.
What is the difference between Matrixyl and Matrixyl 3000?
Matrixyl is palmitoyl pentapeptide-4, Matrixyl 3000 the combination of palmitoyl tripeptide-1 and palmitoyl tetrapeptide-7. The good clinical study belongs to the older pentapeptide. For the combination we found no randomized study of its own in humans.
Is Matrixyl better than Argireline?
In the only head-to-head comparison study, a pilot study with 21 women over 8 weeks, palmitoyl pentapeptide-4 performed better than acetyl hexapeptide-3 and placebo. The study is too small to take this as established.
How long does it take before you see anything?
The clinical studies run for 8 to 12 weeks and measure small improvements over this period. Anyone who expects a difference after two weeks expects more than the data show.
Does the peptide even get deep enough into the skin?
What has been measured is that it reaches all layers of the stratum corneum, in amounts decreasing inward, and apparently sits on the cell surfaces rather than inside the cells. Whether it reaches the collagen-producing cells of the dermis has not been shown in humans.
Can Matrixyl be combined with retinol or vitamin C?
There are no reliable comparison studies on the peptide alone. Many products contain such combinations, and precisely for that reason the peptide’s contribution cannot be isolated from their studies.
Related
- Mentioned togetherGHK-Cu (copper tripeptide)
- Mentioned togetherHyaluronic acid
- Related topicArgireline (acetyl hexapeptide-8)
- Mentioned togetherAstaxanthin
- Mentioned togetherCollagen peptides
- Mentioned togetherVitamin C
Sources
- Robinson et al., Int J Cosmet Sci 2005 (main clinical study)
- Aruan et al., J Clin Aesthet Dermatol 2023 (head-to-head comparison)
- Trzaska et al., Int J Pharm 2026 (penetration into the stratum corneum)
- Vitali et al., Pharmaceutics 2024 (collagen production in cell culture)
- Bjerke et al., Curr Res Toxicol 2026 (safety assessment of cosmetic peptides)
- Pintea et al., Biomolecules 2025 (review of cosmetic peptides)
- Nukaly et al., Front Med 2026 (meta-analysis of peptides)
- Pelin et al., ACS Omega 2026 (derivatives, cell tolerability)
- Murthy et al., Int J Cosmet Sci 2025 (binding to skin components)
Open in the database – with search, filters and comparison (German app)
Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in the hands of a physician. Last updated: 2026-09-30.